Background: Phylloid sarcomas are rare. There is not enough data to codify the
management. Objectives: The objective was to study the clinical and
therapeutic aspects and the fate of patients after a follow-up of at least 4
years. Thus contributing to the limited body of knowledge on these tumors. Methods: a retrospective analysis of the files from 2013 to 2017 was carried out and
patients were followed up until 2021at Hassan II Hospital. Epidemiological,
clinical and therapeutic aspects were studied. Survival was calculated using
the Kaplan-Meier method. Results: We collected 12 charts of patients
treated for phyllodeal sarcoma from 2013 to 2017. The median age was 43 years.
The circumstance of discovery was marked by the presence of nodule in all
patients. The coupled echo-mammography examination classified the nodules, ACR
4 in 7 patients and ACR 3 in 3 and ACR 5 in 2 patients. Histological
examination revealed a phylloid sarcoma in 11 patients and a borderline
phylloid tumor in 1 patient. All patients had radical surgery with positive
margins in 2 patients, 16.66%. One patient had revision surgery. Histological
examination of the surgical specimens showed phylloid sarcoma on all specimens.
All patients had adjuvant radiotherapy with doses of 50 Gy in 25 fractions of 2
Gy and a boost of 10 Gy was done in one patient. The median spread of
radiotherapy was 37 days. Grade 1 and 2 skin toxicities were noted in 5 and 3
patients respectively. The median time from surgery to radiotherapy was 2.95
months. 3 patients relapsed after 13.6 months of follow-up. The recurrence-free
survival at 1 and 3 years was 83% and 75% respectively. Overall survival at 3
and 5 years was 83% and 75% respectively. Conclusion: This is a rare
entity which requires randomized trials to codify its management. It would seem that the multidisciplinary
approach, associating surgery ± radiotherapy, is a good option.
References
[1]
Lakhani, S.R., International Agency for Research on Cancer Press and World Health Organization (2012) WHO Classification of Tumours of the Breast. International Agency for Research on Cancer Press, Lyon.
[2]
Lim, S.Z., Ong, K.W., Tan, B.K., Selvarajan, S. and Tan, P.H. (2016) Sarcoma of the Breast: An Update on a Rare Entity. Journal of Clinical Pathology, 69, 373-381.
https://doi.org/10.1136/jclinpath-2015-203545
[3]
Tavassoli, F.A. and Devilee, P. (2003) Pathology and Genetics of Tumors of the Breast and Female Genital Organs. World Health Organization Classification of Tumors, Vol. 4, International Agency for Research on Cancer Press, Lyon.
[4]
Al-Benna, S., Poggemann, K., Steinau, H.U. and Steinstraesser, L. (2010) Diagnosis and Management of Primary Breast Sarcoma. Breast Cancer Research and Treatment, 122, 619-626. https://doi.org/10.1007/s10549-010-0915-y
[5]
Lahat, G., Lev, D., Gerstenhaber, F., Madewell, J., Le-Petross, H. and Pollock, R.E. (2012) Sarcomas of the Breast. Expert Review of Anticancer Therapy, 12, 1045-1051. https://doi.org/10.1586/era.12.82
[6]
Trent 2nd, I.J., Benjamin, R.S. and Valero, V. (2001) Primary Soft Tissue Sarcoma of the Breast. Current Treatment Options in Oncology, 2, 169-176.
https://doi.org/10.1007/s11864-001-0059-8
[7]
Norris, H.J. and Taylor, H.B. (1968) Sarcomas and Related Mesenchymal Tumors of the Breast. Cancer, 22, 22-28.
https://doi.org/10.1002/1097-0142(196807)22:1%3C22::AID-CNCR2820220105%3E3.0.CO;2-R
[8]
Gabriele, R., Borghese, M., Corigliano, N., Barbaro, M. and Conte, M. (2000) Phyllodes Tumor of the Breast. Personal Contribution of 21 Cases. Il Giornale di chirurgia, 21, 453-456.
[9]
Ranchere-Vince, D., Fontanière, B. and Labadie, M. (1998) Cytopathologie Mammaire. In: EMCGynécologie, Elsevier Masson, Paris. [816-F-10, 10 p].
[10]
Toesca, A., Spitaleri, G., De Pas, T., Botteri, E., Gentilini, O., Bottiglieri, L., et al. (2012) Sarcoma of the Breast: Outcome and Reconstructive Options. Clinical Breast Cancer, 12, 438-444. https://doi.org/10.1016/j.clbc.2012.09.008
[11]
Belkacemi, Y., Bousquet, G., Marsiglia, H., Ray-Coquard, I., Magné, N., Malard, Y., et al. (2008) Phyllodes Tumors of the Breast. International Journal of Radiation Oncology, Biology, Physics, 70, 492-500.
https://doi.org/10.1016/j.ijrobp.2007.06.059
[12]
Confavreux, C., Lurkin, A., Mitton, N., Blondet, R., Saba, C., Ranchere, D., et al. (2006) Sarcomas and Malignant Phyllodes Tumours of the Breast: A Retrospective Study. European Journal of Cancer, 42, 2715-2721.
https://doi.org/10.1016/j.ejca.2006.05.040
[13]
Grenier, J., Delbaldo, C., Zelek, L. and Piedbois, P. (2010) Tumeurs phyllodes et sarcomes dusein: Mise au point. Bulletin du Cancer, 97, 1197-1207.
https://doi.org/10.1684/bdc.2010.1174
[14]
Morales-Vásquez, F., Gonzalez-Angulo, A.M., Broglio, K., Lopez-Basave, H.N., Gallardo, D., Hortobagyi, G.N., et al. (2007) Adjuvant Chemotherapy with Doxorubicin and Dacarbazine Has No Effect in Recurrence-Free Survival of Malignant Phyllodes Tumors of the Breast. The Breast Journal, 13, 551-556.
https://doi.org/10.1111/j.1524-4741.2007.00510.x
[15]
Zurrida, S., Bartoli, C., Galimberti, V., Squicciarini, P., Delledonne, V., Veronesi, P., et al. (1992) Which Therapy for Unexpected Phyllodes Tumour of the Breast? European Journal of Cancer, 28, 654-657.
https://doi.org/10.1016/S0959-8049(05)80119-4
[16]
Stebbing, J.F. and Nash, A.G. (1995) Diagnosis and Management of Phyllodes Tumour of the Breast: Experience of 33 Cases at a Specialist Centre. AAnnals of the Royal College of Surgeons of England, 77, 181-184.
[17]
Zelek, L., Llombart-Cussac, A., Terrier, P., Pivot, X., Guinebretiere, J.M., Le Péchoux, C., et al. (2003) Prognostic Factors in Primary Breast Sarcomas: A Series of Patients with Long-Term Follow-up. Journal of Clinical Oncology, 21, 2583-2588.
https://doi.org/10.1200/JCO.2003.06.080
[18]
Adem, C., Reynolds, C., Ingle, J.N. and Nascimento, A.G. (2004) Primary Breast Sarcoma: Clinico-Pathologic Series from the Mayo Clinic and Review of the Literature. British Journal of Cancer, 91, 237-241.
https://doi.org/10.1038/sj.bjc.6601920
[19]
Fields, R.C., Aft, R.L., Gillanders, W.E., Eberlein, T.J. and Margenthaler, J.A. (2008) Treatment and Outcomes of Patients with Primary Breast Sarcoma. American Journal of Surgery, 196, 559-561. https://doi.org/10.1016/j.amjsurg.2008.06.010
[20]
Berg, J.W., Decrosse, J.J., Fracchia, A.A. and Farrow, J. (1962) Stromal Sarcomas of the Breast: A Unified Approach to Connective Tissue Sarcomas Other than Cystosarcoma phyllodes. Cancer, 15, 418-424.
https://doi.org/10.1002/1097-0142(196203/04)15:2%3C418::AID-CNCR2820150226%3E3.0.CO;2-V
[21]
Bousquet, G., Confavreux, C., Magne, N., de Lara, C.T., Poortmans, P., Senkus, E., et al. (2007) Outcome and Prognostic Factors in Breast Sarcoma: A Multicenter Study from the Rare Cancer Network. Radiotherapy & Oncology, 85, 355-361.
https://doi.org/10.1016/j.radonc.2007.10.015
[22]
Moore, M.P. and Kinne, D.W. (1996) Breast Sarcoma. Surgical Clinics of North America, 76, 383-392. https://doi.org/10.1016/S0039-6109(05)70445-X
